Some 30-50% of Graves' disease patients develop the medically challenging Graves' orbitopathy
characterised by bulging eyes (proptosis), while 3-5% of such patients suffer from a sight-threatening form of Graves' orbitopathy
Involvement of the tendinous insertion of the muscle distinguishes IOIS muscle enlargement from that of thyroid-associated orbitopathy
, in which the tendinous insertion point is spared.
On the back of this, the chapter then describes in turn the clinical features and management of the key differential diagnoses, ie preseptal and orbital cellulitis and thyroid orbitopathy
Claudio Marcocci of the department of endocrinology and metabolism at the University of Pisa (Italy) and his associates in the European Group on Graves' Orbitopathy
The second edition of this question-and-answer reference reflects the past three years of progress in understanding the pathogenesis and treatment of Grave's orbitopathy
(GO) and incorporates the EUGOGO consensus statement on management of GO.
The obvious difference is that our patient had a normal thyroid gland before irradiation and no evidence of orbitopathy
Other endoscopic procedures replacing the more conventional open procedures include endoscopic dacryocystorhinostomy (DCR) for epiphora (watery eye due to nasolacrimal duct obstruction), orbital decompression for Graves' orbitopathy
, optic nerve decompression, drainage of fronto-ethmoidal mucoceles and external fronto-ethmoidectomies for persistent frontal sinus disease.
Eye findings related to Graves orbitopathy
He is an active member of EUGOGO, the European Group on Graves' Orbitopathy
Physical examination was characteristic of very active hyperthyroidism with a diffusely enlarged goiter, two to three times the normal size, and no evidence of active orbitopathy
SEATTLE, Washington, NEW YORK and COPENHAGEN, Denmark, July 29, 2015 /PRNewswire/ -- CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) -- a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy
and other indications.
Moderately severe and active forms of Graves' orbitopathy
can be effectively treated with glucocorticoids, orbital irradiation, or both.